Safety of Mepolizumab for severe eosinophilic refractory asthma in a single-center cohort including a patient with echinococcus hepatic cyst and a patient with lung cancer . A single center one year follow up

Introduction: Mepolizumab is an anti-IL5 humanized antibody approved for severe eosinophilic uncontrolled asthma. Long term safety has been assessed in registration studies, but few data are available on patients with echinococcus hepatic cyst (EHC) or other comorbidities i.e. lung cancer requiring chemotherapy (CT). Aim: analysis of one-year treatment outcomes in 30 patients on treatment with Mepolizumab, including one patient with known EHC and hepatic cyrrosis and one patient on treatment with cisplatin-gemcitabine for lung cancer (stage IV adenocarcinoma ). Methods: All patients were evaluated for blood eosinophylic count, oral corticosteroids (OCS) use and comorbidities in a single-center cohort case-note analysis. Results: Mepolizumab reduced OCS use (p<0.05), decreased blood eosinophils compared to baseline (p<0.01). No impairment of hepatic function or relapse of echinococcus infection was reported in the patients with EHC. No interaction with CT were observed, and lung cancer is actually in clinical stability. Conclusions: Mepolizumab treatment improved asthma outcomes and was not related with hepatic impairment, relapse of EHC and did not affected chemotherapy at one year follow up.